

OCT. 13. 2003 9:44AM

GENAISSANCE PHARM.

NO. 191 P. 1

**PATENT**

**Docket No. MWH-0029US**

**Response (to Office Actions of January 7, 2003, June 26, 2003, and October 7, 2003) filed October 12, 2003**

**U.S. Appl. No. 09/856,803**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Stephen B. Liggett  
Application No.: 09/856,803  
Filed: May 25, 2001 (35 U.S.C. § 371 of PCT/US99/27963, filed November 24, 1999, which claims benefit of U.S. Appl. No. 60/109,886, filed November 25, 1998)  
Confirmation No.: 3706  
Group No.: 1634  
Examiner: Myers, C.  
For: **POLYMORPHISMS IN THE 5' LEADER CISTRON OF THE  $\beta_2$ -ADRENERGIC RECEPTOR**

OFFICIAL

Commissioner for Patents

**Certificate of Facsimile Transmission**

I hereby certify under 37 C.F.R. § 1.8 that this correspondence is being transmitted by facsimile to the United States Patent and Trademark Office, Commissioner for Patents, TC 1600, at (703) 872-9306, on 10-12-03.

  
Matthew M. Catlett

RECEIVED  
CENTRAL FAX CENTER

**RESPONSE TO OFFICE ACTION UNDER 37 C.F.R. § 1.111**

OCT 14 2003

In response to the Office Actions dated January 7, 2003, June 26, 2003, and October 12, 2003 regarding the above-captioned application, please amend the application as follows:

**Amendments to the Claims begin on page 2 of this paper.**

**Remarks begin on page 6 of this paper.**